Corsera Health Announces $80 Million Series A Financing and Reaches Key Clinical Milestone
– Financing co-led by Forbion and Population Health Partners – – Dosing initiated in Phase 1 clinical trial of COR-1004, a novel PCSK9 siRNA – BOSTON–(BUSINESS WIRE)–Corsera Health, Inc., a clinical-stage company leading the future of…